Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis
Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current syste...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sadeghi, Sara [verfasserIn] Kalantari, Yasamin [verfasserIn] Shokri, Sima [verfasserIn] Fallahpour, Morteza [verfasserIn] Nafissi, Nahid [verfasserIn] Goodarzi, Azadeh [verfasserIn] Valizadeh, Rohollah [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Journal of clinical virology - Amsterdam [u.a.] : Elsevier Science, 1993, 153 |
|---|---|
| Übergeordnetes Werk: |
volume:153 |
| DOI / URN: |
10.1016/j.jcv.2022.105196 |
|---|
| Katalog-ID: |
ELV058278974 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV058278974 | ||
| 003 | DE-627 | ||
| 005 | 20230926162515.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220808s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jcv.2022.105196 |2 doi | |
| 035 | |a (DE-627)ELV058278974 | ||
| 035 | |a (ELSEVIER)S1386-6532(22)00129-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.43 |2 bkl | ||
| 100 | 1 | |a Sadeghi, Sara |e verfasserin |0 (orcid)0000-0002-1657-1487 |4 aut | |
| 245 | 1 | 0 | |a Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis |
| 264 | 1 | |c 2022 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. | ||
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Vaccination | |
| 650 | 4 | |a Immunization | |
| 650 | 4 | |a Children | |
| 650 | 4 | |a Adolescents | |
| 650 | 4 | |a Immunosuppressed | |
| 650 | 4 | |a Systematic review | |
| 700 | 1 | |a Kalantari, Yasamin |e verfasserin |4 aut | |
| 700 | 1 | |a Shokri, Sima |e verfasserin |4 aut | |
| 700 | 1 | |a Fallahpour, Morteza |e verfasserin |4 aut | |
| 700 | 1 | |a Nafissi, Nahid |e verfasserin |4 aut | |
| 700 | 1 | |a Goodarzi, Azadeh |e verfasserin |4 aut | |
| 700 | 1 | |a Valizadeh, Rohollah |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical virology |d Amsterdam [u.a.] : Elsevier Science, 1993 |g 153 |h Online-Ressource |w (DE-627)306654539 |w (DE-600)1499932-8 |w (DE-576)121465446 |x 1873-5967 |7 nnns |
| 773 | 1 | 8 | |g volume:153 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_2336 | ||
| 936 | b | k | |a 44.43 |j Medizinische Mikrobiologie |q VZ |
| 951 | |a AR | ||
| 952 | |d 153 | ||
| author_variant |
s s ss y k yk s s ss m f mf n n nn a g ag r v rv |
|---|---|
| matchkey_str |
article:18735967:2022----::muooirsosefccadaeyfacnsgiscvd9netoihatynimnsprsecideaddlsetae |
| hierarchy_sort_str |
2022 |
| bklnumber |
44.43 |
| publishDate |
2022 |
| allfields |
10.1016/j.jcv.2022.105196 doi (DE-627)ELV058278974 (ELSEVIER)S1386-6532(22)00129-9 DE-627 ger DE-627 rda eng 610 VZ 44.43 bkl Sadeghi, Sara verfasserin (orcid)0000-0002-1657-1487 aut Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. COVID-19 Vaccination Immunization Children Adolescents Immunosuppressed Systematic review Kalantari, Yasamin verfasserin aut Shokri, Sima verfasserin aut Fallahpour, Morteza verfasserin aut Nafissi, Nahid verfasserin aut Goodarzi, Azadeh verfasserin aut Valizadeh, Rohollah verfasserin aut Enthalten in Journal of clinical virology Amsterdam [u.a.] : Elsevier Science, 1993 153 Online-Ressource (DE-627)306654539 (DE-600)1499932-8 (DE-576)121465446 1873-5967 nnns volume:153 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_2004 GBV_ILN_2336 44.43 Medizinische Mikrobiologie VZ AR 153 |
| spelling |
10.1016/j.jcv.2022.105196 doi (DE-627)ELV058278974 (ELSEVIER)S1386-6532(22)00129-9 DE-627 ger DE-627 rda eng 610 VZ 44.43 bkl Sadeghi, Sara verfasserin (orcid)0000-0002-1657-1487 aut Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. COVID-19 Vaccination Immunization Children Adolescents Immunosuppressed Systematic review Kalantari, Yasamin verfasserin aut Shokri, Sima verfasserin aut Fallahpour, Morteza verfasserin aut Nafissi, Nahid verfasserin aut Goodarzi, Azadeh verfasserin aut Valizadeh, Rohollah verfasserin aut Enthalten in Journal of clinical virology Amsterdam [u.a.] : Elsevier Science, 1993 153 Online-Ressource (DE-627)306654539 (DE-600)1499932-8 (DE-576)121465446 1873-5967 nnns volume:153 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_2004 GBV_ILN_2336 44.43 Medizinische Mikrobiologie VZ AR 153 |
| allfields_unstemmed |
10.1016/j.jcv.2022.105196 doi (DE-627)ELV058278974 (ELSEVIER)S1386-6532(22)00129-9 DE-627 ger DE-627 rda eng 610 VZ 44.43 bkl Sadeghi, Sara verfasserin (orcid)0000-0002-1657-1487 aut Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. COVID-19 Vaccination Immunization Children Adolescents Immunosuppressed Systematic review Kalantari, Yasamin verfasserin aut Shokri, Sima verfasserin aut Fallahpour, Morteza verfasserin aut Nafissi, Nahid verfasserin aut Goodarzi, Azadeh verfasserin aut Valizadeh, Rohollah verfasserin aut Enthalten in Journal of clinical virology Amsterdam [u.a.] : Elsevier Science, 1993 153 Online-Ressource (DE-627)306654539 (DE-600)1499932-8 (DE-576)121465446 1873-5967 nnns volume:153 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_2004 GBV_ILN_2336 44.43 Medizinische Mikrobiologie VZ AR 153 |
| allfieldsGer |
10.1016/j.jcv.2022.105196 doi (DE-627)ELV058278974 (ELSEVIER)S1386-6532(22)00129-9 DE-627 ger DE-627 rda eng 610 VZ 44.43 bkl Sadeghi, Sara verfasserin (orcid)0000-0002-1657-1487 aut Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. COVID-19 Vaccination Immunization Children Adolescents Immunosuppressed Systematic review Kalantari, Yasamin verfasserin aut Shokri, Sima verfasserin aut Fallahpour, Morteza verfasserin aut Nafissi, Nahid verfasserin aut Goodarzi, Azadeh verfasserin aut Valizadeh, Rohollah verfasserin aut Enthalten in Journal of clinical virology Amsterdam [u.a.] : Elsevier Science, 1993 153 Online-Ressource (DE-627)306654539 (DE-600)1499932-8 (DE-576)121465446 1873-5967 nnns volume:153 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_2004 GBV_ILN_2336 44.43 Medizinische Mikrobiologie VZ AR 153 |
| allfieldsSound |
10.1016/j.jcv.2022.105196 doi (DE-627)ELV058278974 (ELSEVIER)S1386-6532(22)00129-9 DE-627 ger DE-627 rda eng 610 VZ 44.43 bkl Sadeghi, Sara verfasserin (orcid)0000-0002-1657-1487 aut Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis 2022 nicht spezifiziert zzz rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. COVID-19 Vaccination Immunization Children Adolescents Immunosuppressed Systematic review Kalantari, Yasamin verfasserin aut Shokri, Sima verfasserin aut Fallahpour, Morteza verfasserin aut Nafissi, Nahid verfasserin aut Goodarzi, Azadeh verfasserin aut Valizadeh, Rohollah verfasserin aut Enthalten in Journal of clinical virology Amsterdam [u.a.] : Elsevier Science, 1993 153 Online-Ressource (DE-627)306654539 (DE-600)1499932-8 (DE-576)121465446 1873-5967 nnns volume:153 GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_2004 GBV_ILN_2336 44.43 Medizinische Mikrobiologie VZ AR 153 |
| language |
English |
| source |
Enthalten in Journal of clinical virology 153 volume:153 |
| sourceStr |
Enthalten in Journal of clinical virology 153 volume:153 |
| format_phy_str_mv |
Article |
| bklname |
Medizinische Mikrobiologie |
| institution |
findex.gbv.de |
| topic_facet |
COVID-19 Vaccination Immunization Children Adolescents Immunosuppressed Systematic review |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Journal of clinical virology |
| authorswithroles_txt_mv |
Sadeghi, Sara @@aut@@ Kalantari, Yasamin @@aut@@ Shokri, Sima @@aut@@ Fallahpour, Morteza @@aut@@ Nafissi, Nahid @@aut@@ Goodarzi, Azadeh @@aut@@ Valizadeh, Rohollah @@aut@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
306654539 |
| dewey-sort |
3610 |
| id |
ELV058278974 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV058278974</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230926162515.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcv.2022.105196</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV058278974</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1386-6532(22)00129-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.43</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sadeghi, Sara</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-1657-1487</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">COVID-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunization</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Children</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adolescents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunosuppressed</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systematic review</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kalantari, Yasamin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shokri, Sima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fallahpour, Morteza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nafissi, Nahid</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodarzi, Azadeh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Valizadeh, Rohollah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of clinical virology</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier Science, 1993</subfield><subfield code="g">153</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)306654539</subfield><subfield code="w">(DE-600)1499932-8</subfield><subfield code="w">(DE-576)121465446</subfield><subfield code="x">1873-5967</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.43</subfield><subfield code="j">Medizinische Mikrobiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">153</subfield></datafield></record></collection>
|
| author |
Sadeghi, Sara |
| spellingShingle |
Sadeghi, Sara ddc 610 bkl 44.43 misc COVID-19 misc Vaccination misc Immunization misc Children misc Adolescents misc Immunosuppressed misc Systematic review Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis |
| authorStr |
Sadeghi, Sara |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)306654539 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1873-5967 |
| topic_title |
610 VZ 44.43 bkl Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis COVID-19 Vaccination Immunization Children Adolescents Immunosuppressed Systematic review |
| topic |
ddc 610 bkl 44.43 misc COVID-19 misc Vaccination misc Immunization misc Children misc Adolescents misc Immunosuppressed misc Systematic review |
| topic_unstemmed |
ddc 610 bkl 44.43 misc COVID-19 misc Vaccination misc Immunization misc Children misc Adolescents misc Immunosuppressed misc Systematic review |
| topic_browse |
ddc 610 bkl 44.43 misc COVID-19 misc Vaccination misc Immunization misc Children misc Adolescents misc Immunosuppressed misc Systematic review |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Journal of clinical virology |
| hierarchy_parent_id |
306654539 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Journal of clinical virology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)306654539 (DE-600)1499932-8 (DE-576)121465446 |
| title |
Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis |
| ctrlnum |
(DE-627)ELV058278974 (ELSEVIER)S1386-6532(22)00129-9 |
| title_full |
Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis |
| author_sort |
Sadeghi, Sara |
| journal |
Journal of clinical virology |
| journalStr |
Journal of clinical virology |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| author_browse |
Sadeghi, Sara Kalantari, Yasamin Shokri, Sima Fallahpour, Morteza Nafissi, Nahid Goodarzi, Azadeh Valizadeh, Rohollah |
| container_volume |
153 |
| class |
610 VZ 44.43 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sadeghi, Sara |
| doi_str_mv |
10.1016/j.jcv.2022.105196 |
| normlink |
(ORCID)0000-0002-1657-1487 |
| normlink_prefix_str_mv |
(orcid)0000-0002-1657-1487 |
| dewey-full |
610 |
| author2-role |
verfasserin |
| title_sort |
immunologic response, efficacy, and safety of vaccines against covid-19 infection in healthy and immunosuppressed children and adolescents aged 2 – 21 years old: a systematic review and meta-analysis |
| title_auth |
Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis |
| abstract |
Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. |
| abstractGer |
Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. |
| abstract_unstemmed |
Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_2004 GBV_ILN_2336 |
| title_short |
Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis |
| remote_bool |
true |
| author2 |
Kalantari, Yasamin Shokri, Sima Fallahpour, Morteza Nafissi, Nahid Goodarzi, Azadeh Valizadeh, Rohollah |
| author2Str |
Kalantari, Yasamin Shokri, Sima Fallahpour, Morteza Nafissi, Nahid Goodarzi, Azadeh Valizadeh, Rohollah |
| ppnlink |
306654539 |
| mediatype_str_mv |
c |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1016/j.jcv.2022.105196 |
| up_date |
2024-07-06T18:33:44.614Z |
| _version_ |
1803855671711498240 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV058278974</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230926162515.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220808s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.jcv.2022.105196</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV058278974</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1386-6532(22)00129-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.43</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sadeghi, Sara</subfield><subfield code="e">verfasserin</subfield><subfield code="0">(orcid)0000-0002-1657-1487</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 – 21 years old: A Systematic Review and Meta-analysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Children and adolescents form a large proportion of societies and play an important role in the transmission of COVID-19. On the other hand, their education, mental and physical wellness, and safety are compromised which makes vaccination a crucial step to return to normal life. In the current systematic review, the COVID-19 vaccination was evaluated in a total of 50,148 children and adolescents in 22 published studies and 5,279 participants in two ongoing clinical trials. The study was registered in the PROSPERO with the ID# CRD42022303615. Data were collected about multiple vaccines including BNT162b2 (Pfizer), mRNA-1273 (Moderna), JNJ-78436735 (Johnson and Johnson), CoronaVac (Sinovac), BBIBP-CorV (Sinopharm), adenovirus type-5-vectored vaccine, ZyCov-D, and BBV152 (COVAXIN). The immune response and efficacy of such vaccines were 96% – 100% in healthy children and adolescents and were also acceptable in those with underlying diseases and suppressed immune systems. The current systematic review revealed favorable safety profiles of employed vaccines in children and adolescents; however, adverse reactions such as myocarditis and myopericarditis were reported which were transient and resolved entirely. Consequently, vaccinating children and adolescents aged 2 – 21 years old is beneficial to abort the COVID-19 pandemic. Moreover, the risk-benefit assessments revealed favorable results for vaccinating children and adolescents, especially those with underlying diseases and immunosuppressed conditions, alongside adults to prevent transmission, severe infection, negative outcomes, and new variants formation. Also, according to the meta-analysis, the efficacy and immune response of vaccines after the first and second doses were 91% and 92%, respectively. Meanwhile, overall immune response for all vaccines was 95% and 91% for Pfizer vaccine.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">COVID-19</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vaccination</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunization</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Children</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Adolescents</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Immunosuppressed</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Systematic review</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kalantari, Yasamin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shokri, Sima</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fallahpour, Morteza</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nafissi, Nahid</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Goodarzi, Azadeh</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Valizadeh, Rohollah</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Journal of clinical virology</subfield><subfield code="d">Amsterdam [u.a.] : Elsevier Science, 1993</subfield><subfield code="g">153</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)306654539</subfield><subfield code="w">(DE-600)1499932-8</subfield><subfield code="w">(DE-576)121465446</subfield><subfield code="x">1873-5967</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:153</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2004</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2336</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.43</subfield><subfield code="j">Medizinische Mikrobiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">153</subfield></datafield></record></collection>
|
| score |
7.400448 |